Valiant Laboratories Analyst Review May 2026

This Valiant Laboratories analyst review for May 2026 covers the key data investors need for VLIANT at its current price of Rs 520. Valiant Laboratories (NSE: VLIANT) is a pharmaceutical API company with a market capitalisation of approximately Rs 1,800 crore, specialising in veterinary APIs and specialty pharmaceutical molecules. The analyst consensus target of Rs 640 implies meaningful upside, and this Valiant Laboratories analyst review examines technical levels, business performance, valuation, and key risks for VLIANT through FY27.

Click Here – Get Free Investment Predictions

Valiant Laboratories Company Snapshot May 2026

Valiant Laboratories manufactures veterinary APIs (albendazole, ivermectin), human pharma intermediates, and specialty molecules for regulated markets. Low-cost manufacturing in Gujarat and regulatory approvals in the US and Europe drive exports. The table below summarises the key data referenced in this Valiant Laboratories analyst review.

Parameter	Value
NSE Ticker	VLIANT
Sector	Pharmaceuticals – APIs
CMP (May 2026)	Rs 520
52 Week High	Rs 720
52 Week Low	Rs 440
Market Cap	Rs 1,800 Crore
Trailing P/E	25x
Analyst Consensus Target	Rs 640
Bull Case Target	Rs 780
Bear Case Target	Rs 420

Analyst Insight in This Valiant Laboratories Analyst Review

Senior Research Analyst Ankit Jaiswal flags Valiant Laboratories as a stock to watch in May 2026. At Rs 520, Ankit Jaiswal identifies key support in the Rs 449 to Rs 494 band and resistance near Rs 551. He suggests watching Valiant Laboratories for a potential move toward Rs 640, subject to Pharmaceuticals – APIs sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Valiant Laboratories analyst review and does not constitute a trade recommendation.

Technical Analysis in This Valiant Laboratories Analyst Review

At Rs 520, VLIANT is trading within its 52-week band of Rs 440 to Rs 720. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 449 to Rs 494 band while resistance is seen in the Rs 551 to Rs 580 zone. A sustained move above Rs 551 could open the path toward the analyst consensus target of Rs 640 as identified in this Valiant Laboratories analyst review.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 449 to Rs 494 – investors tracking this Valiant Laboratories analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for VLIANT.
• Resistance Zone: Rs 551 to Rs 580 – a sustained close above Rs 551 would be a positive breakout signal worth flagging in this Valiant Laboratories analyst review.
• Medium-Term Target: The analyst consensus of Rs 640 represents the base-case upside scenario in this Valiant Laboratories analyst review.

Business Segment Analysis

Veterinary APIs (Albendazole, Ivermectin – Core)

This is the primary revenue and margin driver for Valiant Laboratories, directly supporting the earnings trajectory toward the consensus target of Rs 640.

Human Pharmaceutical APIs and Intermediates

This segment adds scale and diversification to Valiant Laboratories’s business model and is a meaningful EPS contributor through FY27 and FY28.

Regulated Market Exports (US, Europe, Japan)

This represents the medium-term growth frontier for Valiant Laboratories and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Valiant Laboratories Analyst Review

At Rs 520, Valiant Laboratories trades at a trailing P/E of 25x. This Valiant Laboratories analyst review presents three scenarios: a bull case of Rs 780 on strong earnings delivery, a base case of Rs 640 at analyst consensus, and a bear case of Rs 420 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Valiant Laboratories analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 780	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 640	Moderate growth, analyst consensus estimate
Bear Case	Rs 420	Earnings miss or macro headwinds

Trade Outlook for Valiant Laboratories

Based on the technical and fundamental analysis in this Valiant Laboratories analyst review, investors might watch VLIANT near the support zone of Rs 449 to Rs 494 for potential opportunities. A flag above Rs 551 could suggest improving momentum toward Rs 640. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Valiant Laboratories in FY27

A well-rounded Valiant Laboratories analyst review must assess downside risks. Key risks for Valiant Laboratories include a macro slowdown affecting Pharmaceuticals – APIs sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in VLIANT.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Valiant Laboratories Analyst Review Verdict for 2026

This Valiant Laboratories analyst review concludes that at Rs 520, VLIANT offers a defined risk-reward with a consensus target of Rs 640. The 52-week range of Rs 440 to Rs 720 provides context on the current entry point. Use this Valiant Laboratories analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on VLIANT.

Frequently Asked Questions: Valiant Laboratories Analyst Review 2026

What is the analyst target for Valiant Laboratories in 2026?

The analyst consensus target is Rs 640, with a bull case of Rs 780 and a bear case of Rs 420. This Valiant Laboratories analyst review recommends monitoring Q1 FY27 earnings for confirmation.

Is Valiant Laboratories a good investment at Rs 520?

At Rs 520 with a P/E of 25x and a consensus target of Rs 640, this Valiant Laboratories analyst review is constructive for medium to long-term investors in the Pharmaceuticals – APIs sector. Always consult a SEBI-registered advisor before investing.

What is Valiant Laboratories’s 52-week high and low?

The 52-week high is Rs 720 and the 52-week low is Rs 440. At Rs 520, VLIANT is positioned within this range as noted in this Valiant Laboratories analyst review.

What are the key risks for Valiant Laboratories?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – APIs sector as assessed in this Valiant Laboratories analyst review.

Where can I track live data for Valiant Laboratories?

Track Valiant Laboratories’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Valiant Laboratories analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.